Network Medicine‐Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD‐L1 Expression via Targeting SPOP in Cancer
Advanced Science · 2025
DOI: 10.1002/advs.202410285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Saisai Tian und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Phytochemistry, School of Pharmacy, Second Military Medical University, Shanghai, 200433, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Drug Repositioning, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Municipal Science and Technology Major Project.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) are drugs that inhibit immune checkpoint (ICP) molecules to restore the antitumor activity of immune cells and eliminate tumor cells. Due to the limitations and certain side effects of current ICIs, such as programmed death protein‐1, programmed cell death‐ligand 1, and cytotoxic T lymphocyte‐associated antigen 4 (CTLA4) antibodies, there is an urgent need to find new drugs with ICP inhibitory effects. In this study, a network‐based computational framework called m ulti‐ net work algorithm‐driven d rug r epositioning targeting I CP ( Mnet‐DRI ) is developed to accurately repurpose novel ICIs from ≈3000 Food and Drug Administration‐approved or investigational drugs. By applying Mnet‐DRI to PD‐L1, maprotiline (MAP), an antidepressant drug is repurposed, as a potential PD‐L1 modifier for colorectal and lung cancers. Experimental validation revealed that MAP reduced PD‐L1 expression by targeting E3 ubiquitin ligase speckle‐type zinc finger structural protein (SPOP), and the combination of MAP and anti‐CTLA4 in vivo significantly enhanced the antitumor effect, providing a new alternative for the clinical treatment of colorectal and lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Phytochemistry, School of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
- Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
- Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
- Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
- Department of Respiratory and Critical Care, Emergency and Critical Care Medical Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
- State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China.
ORCID-Profile: Sanhong Liu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shanghai Municipal Science and Technology Major Project
- Ability establishment of sustainable use for valuable Chinese medicine resources
- Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences
- Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine
- Chenguang Program of Shanghai Education Development Foundation and Shanghai Municipal Education Commission
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Tian, S., Xu, M., Geng, X., Fang, J., Xu, H., Xue, X., Hu, H., Zhang, Q., Yu, D., Guo, M., Zhang, H., Lu, J., Guo, C., Wang, Q., Liu, S., & Zhang, W. (2025). Network Medicine‐Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD‐L1 Expression via Targeting SPOP in Cancer. Advanced Science. https://doi.org/10.1002/advs.202410285
Vancouver
Tian S, Xu M, Geng X, Fang J, Xu H, Xue X, et al. Network Medicine‐Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD‐L1 Expression via Targeting SPOP in Cancer. Advanced Science. 2025. doi:10.1002/advs.202410285
BibTeX
@article{Tian2025,
author = {Tian, Saisai and Xu, Mengting and Geng, Xiangxin and Fang, Jiansong and Xu, Hanchen and Xue, Xinying and Hu, Hongmei and Zhang, Qing and Yu, Dianping and Guo, Mengmeng and Zhang, Hongwei and Lu, Jinyuan and Guo, Chengyang and Wang, Qun and Liu, Sanhong and Zhang, Weidong},
title = {Network Medicine‐Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD‐L1 Expression via Targeting SPOP in Cancer},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202410285}
}
EUVIMED